All In Biotech

Drug Trial Radar · NCT05979818

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

Oct 31, 2028

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
First posted
Aug 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective multi-center Phase Ib/II clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta-adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.

Conditions

  • Non Small Cell Lung Cancer
  • Propranolol
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • β-adrenergic Antagonists
  • Emotional Distress
  • PD-1 Inhibitors

Interventions

  • Propranolol hydrochlorideDrug

    Dose-escalation: 10 mg PO BID, 10 mg PO TID, and 20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • SintilimabDrug

    intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • ChemotherapyDrug

    Platinum-based chemotherapy: For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4/6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • Propranolol hydrochloride matching placeboDrug

    20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • Propranolol Hydrochloride R2PDDrug

    20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs) (BRIO-I)Time frame: 2 years
  2. Recommended phase II dose (RP2D) (BRIO-I)Time frame: 2 years
  3. Objective Response Rate (ORR) (BRIO-I)Time frame: 2 years
  4. Progression-free survival (PFS) (BRIO-II)Time frame: 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital of Central south University

    Changsha, Hunan, China · Recruiting

  • Xiangya hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.